Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 13, 2004. The report details changes in directors' interests in the company's Ordinary Shares and American Depositary Shares (ADSs) resulting from transactions within employee benefit plans.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction data rather than consolidated financial performance.
- Share Sale Price (GBP): £11.07 per Ordinary Share.
- Share Sale Price (USD): US$43.2492 per ADS.
- Plan Fund Average Price: $43.39 per Ordinary Share ADR.
Material Changes
The filing reports specific movements in shareholdings held by employee trusts and retirement plans on February 12, 2004:
- GSK Trust Sales: 121,727 Ordinary Shares were sold on behalf of Performance Share Plan participants.
- ADS Conversion and Sale: 98,514 Ordinary Shares were converted to 49,257 ADSs and subsequently sold.
- Share Transfers: 1,611 Ordinary Shares were transferred to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Retirement Plan Movement: The GlaxoSmithKline US Retirement Savings Plan saw a decrease in holdings from 18,473,127 to 18,460,173 Ordinary Share ADRs.
Outlook, Risks, and Management Commentary
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It serves strictly as a regulatory disclosure of director and employee trust share movements.
Investor Verification Checklist
- Verify the impact of the reported share sales on the company's total outstanding share count.
- Confirm the specific directors (Dr. J-P Garnier, Dr. T Yamada, Mr. J D Coombe) with indirect interests in the GSK Trust and US Retirement Savings Plan.
- Review the full annual report (Form 20-F) for comprehensive financial metrics not included in this 6-K.